



Announcement Summary

Entity name

NEXALIS THERAPEUTICS LTD

Date of this announcement

Tuesday July 14, 2026

The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
NX1AG	PERFORMANCE RIGHTS	4,120,019	14/07/2026

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

NEXALIS THERAPEUTICS LTD

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ACN

Registration number

611845820

1.3 ASX issuer code

NX1

1.4 The announcement is

New announcement

1.5 Date of this announcement

14/7/2026



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

has an existing ASX security code ("existing class")



Part 3B - number and type of +securities the subject of this notification (existing class) where issue has not previously been notified to ASX in an Appendix 3B

ASX +security code and description

NX1AG : PERFORMANCE RIGHTS

Date the +securities the subject of this notification were issued

14/7/2026

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

Yes

Provide details of the KMP or +associates being issued +securities.

Name of KMP	Name of registered holder	Number of +securities
Sean Williams	TG ADVISORY PTY LTD <WILLIAMS GLENAIR FAMILY A/C>	2,641,477

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Please refer the 2026 AGM Notice of Meeting:
<https://nexalitherapeutics.com/investors/announcements/>

Any other information the entity wishes to provide about the +securities the subject of this notification

Please also refer to the announcement dated 14 July 2026 for details on the calculation of the deemed issue price per Share Right.

Issue details**Number of +securities**

4,120,019

Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)

ASX +security code and description	Total number of +securities on issue
NX1 : ORDINARY FULLY PAID	253,037,323

4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
NX1AA : OPTION EXPIRING 14-DEC-2026 EX \$0.20	4,000,000
NX1AK : OPTION EXPIRING 22-DEC-2027 EX \$0.042	23,154,603
NX1AG : PERFORMANCE RIGHTS	11,470,564
NX1AH : OPTION EXPIRING 07-JUL-2028 EX \$0.12	1,000,000
NX1AC : OPTION EXPIRING 11-JUL-2026 EX \$0.15	4,000,000
NX1AD : OPTION EXPIRING 31-DEC-2029 EX \$0.025	38,449,145
NX1AI : OPTION EXPIRING 31-OCT-2028 EX \$0.12	500,000
NX1AF : OPTION EXPIRING 03-JUN-2027 EX \$0.15	2,000,000



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

No

5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

Yes

5.2a Date of meeting or proposed meeting to approve the issue under listing rule 7.1

29/5/2026